Zeitschriftenartikel zum Thema „Caleb T“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Caleb T" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Whitlark, Jason. „Listen, Understand, Obey: Essays on Hebrews in Honor of Gareth Lee Cockerill ed. by Caleb T. Friedman“. Catholic Biblical Quarterly 82, Nr. 1 (2020): 164–65. http://dx.doi.org/10.1353/cbq.2020.0040.
Der volle Inhalt der QuelleBorker, Parth, Yi Bao, Yuanyuan Qiao, Arul Chinnaiyan, Jae Eun Choi, Yuping Zhang, Rahul Mannan et al. „Abstract 7479: Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 7479. http://dx.doi.org/10.1158/1538-7445.am2024-7479.
Der volle Inhalt der QuelleLiu, Vincent, Katalin Sandor, Bence Daniel, Lionel Berthoin, Shan Sabri, Sofia Panagiotopoulou, Yajie Yin et al. „Abstract 1701: Single-cell multi-omic profiling and clonal tracing of the human gynecological tumor microenvironment“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 1701. http://dx.doi.org/10.1158/1538-7445.am2022-1701.
Der volle Inhalt der QuelleHurvitz, Sara, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min-Hwan Kim et al. „Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03“. Cancer Research 82, Nr. 4_Supplement (15.02.2022): GS3–01—GS3–01. http://dx.doi.org/10.1158/1538-7445.sabcs21-gs3-01.
Der volle Inhalt der QuelleFan, Zenghua, David Y. Oh, Anthony Wong, Katsuto Shinohara, Hao Nguyen, Caleb Hwang, Hewitt Chang et al. „Abstract 4988: Responders to combination radiation and PD-1 blockade demonstrate reduced myeloid immunosuppression and enhanced interferon signaling in oligometastatic prostate cancer patients“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 4988. http://dx.doi.org/10.1158/1538-7445.am2024-4988.
Der volle Inhalt der QuelleLafargue, Audrey M., Hailun Wang, Sivarajan T. Chettiar, Rajendra P. Gajula, Amol C. Shetty, Yang Song, Brian W. Simons et al. „Abstract 2968: TWIST1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of TWIST1“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 2968. http://dx.doi.org/10.1158/1538-7445.am2024-2968.
Der volle Inhalt der QuelleTien, Jean C., Yu Chang, Yuping Zhang, Jonathan Chou, Yunhui Cheng, Xiaoju Wang, Jianzhang Yang et al. „Abstract PR010: CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality“. Molecular Cancer Therapeutics 23, Nr. 6_Supplement (10.06.2024): PR010. http://dx.doi.org/10.1158/1538-8514.synthleth24-pr010.
Der volle Inhalt der QuelleDai, Chaobin, Bin Zhang, Yunyang Liao, Qicai Liu, Feiguang Wu, Xiaoting Lv, Kai Zeng und Xiaofeng Zhu. „CALCB rs3829222 T/T Genotype and Low Expression of CALCB Are High-Risk Factors for Adenoid Cystic Carcinoma of Salivary Gland“. Disease Markers 2021 (12.06.2021): 1–5. http://dx.doi.org/10.1155/2021/5546858.
Der volle Inhalt der QuelleBUENO, VINICIUS R., MORGAN R. GOSTEL und GUSTAVO HEIDEN. „The spiraling story of Tyleropappus and a new name for Calea (Asteraceae: Neurolaeneae) from Venezuela“. Phytotaxa 622, Nr. 1 (24.10.2023): 75–84. http://dx.doi.org/10.11646/phytotaxa.622.1.5.
Der volle Inhalt der QuelleAlkashgari, Hossam, Cornelia Stoian, Caleb Ruiz-Jimenez, Jacqueline Coats, Carlos A. Casiano, Sinisa Dovat und Kimberly J. Payne. „Abstract 1528: Molecular mechanisms of TSLP as a therapy for CRLF2 B-Cell acute lymphoblastic leukemia“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 1528. http://dx.doi.org/10.1158/1538-7445.am2022-1528.
Der volle Inhalt der QuelleMuffly, Lori, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger et al. „Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia“. Blood Advances 6, Nr. 14 (15.07.2022): 4085–92. http://dx.doi.org/10.1182/bloodadvances.2022007197.
Der volle Inhalt der QuelleEston, Roger G., Gaynor Parfitt, Laura Campbell und Kevin L. Lamb. „Reliability of Effort Perception for Regulating Exercise Intensity in Children Using the Cart and Load Effort Rating (CALER) Scale“. Pediatric Exercise Science 12, Nr. 4 (November 2000): 388–97. http://dx.doi.org/10.1123/pes.12.4.388.
Der volle Inhalt der QuelleKaufman, P. A., G. Broadwater, K. Lezon-Geyda, L. G. Dressler, D. Berry, P. Friedman, E. P. Winer et al. „CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)“. Journal of Clinical Oncology 25, Nr. 18_suppl (20.06.2007): 1009. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1009.
Der volle Inhalt der QuelleHayes, D. F., A. Thor, L. Dressler, D. Weaver, G. Broadwater, L. Goldstein, S. Martino, J. Ingle, I. C. Henderson und D. Berry. „HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 510. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.510.
Der volle Inhalt der QuelleMrózek, Krzysztof, Andrew J. Carroll, Kati Maharry, Kathleen W. Rao, Shivanand R. Patil, Mark J. Pettenati, Michael S. Watson et al. „Central Review of Cytogenetics Is Essential for Cooperative Group Clinical and Correlative Studies of Acute Leukemia: The Cancer and Leukemia Group B (CALGB) 8461 Experience.“ Blood 104, Nr. 11 (16.11.2004): 1081. http://dx.doi.org/10.1182/blood.v104.11.1081.1081.
Der volle Inhalt der QuelleGajewski, T. F., D. Niedzwiecki, J. Johnson, G. Linette, C. Bucher, M. Blaskovich, S. Sebti und F. Haluska. „Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 8014. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.8014.
Der volle Inhalt der QuelleLozanski, Gerard, Ben Sanford, Krzysztof Mrozek, Colin Edwards, Rebecca Pearson, Clara D. Bloomfield, Richard A. Larson und Wendy Stock. „Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102).“ Blood 110, Nr. 11 (16.11.2007): 2386. http://dx.doi.org/10.1182/blood.v110.11.2386.2386.
Der volle Inhalt der QuelleGiordano, S. H., Z. Duan, Y. F. Kuo, G. N. Hortobagyi, J. Freeman und J. S. Goodwin. „The impact of CALGB 9344 on adjuvant taxane (T) Use for breast cancer (BC)“. Journal of Clinical Oncology 23, Nr. 16_suppl (Juni 2005): 669. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.669.
Der volle Inhalt der QuelleWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, Kanti R. Rai, Richard A. Larson und John C. Byrd. „Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712“. Journal of Clinical Oncology 29, Nr. 10 (01.04.2011): 1349–55. http://dx.doi.org/10.1200/jco.2010.31.1811.
Der volle Inhalt der QuelleStradomska, Dominika, Monika Heba, Aleksandra Czernek, Nikodem Kuźnik, Danuta Gillner, Katarzyna Maresz, Wojciech Pudło, Andrzej Jarzębski und Katarzyna Szymańska. „Lipase Immobilized on MCFs as Biocatalysts for Kinetic and Dynamic Kinetic Resolution of sec-Alcohols“. Catalysts 11, Nr. 4 (20.04.2021): 518. http://dx.doi.org/10.3390/catal11040518.
Der volle Inhalt der QuelleMiura, D., Y. Saitoh, T. Iwatani, H. Kawabata und N. Inoshita. „Chromosome enumeration probe 17 (CEP) ratio to predict chemosensitivity in HER-2 overexpressing breast cancer“. Journal of Clinical Oncology 27, Nr. 15_suppl (20.05.2009): e11600-e11600. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e11600.
Der volle Inhalt der QuelleCzuczman, Myron S., Pierluigi Porcu, Jeffrey Johnson, Donna Niedzwiecki, Michael Kelly, Eric D. Hsi, James R. Cook, George Canellos, Bruce D. Cheson und For the Cancer and Leukemia Group B. „Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901“. Leukemia & Lymphoma 48, Nr. 1 (Januar 2007): 97–103. http://dx.doi.org/10.1080/10428190600961058.
Der volle Inhalt der QuelleRaychaudhuri, Suravi, Ilana Yurkiewicz, Gabriel N. Mannis, Bruno C. Medeiros, Steve E. Coutre, Lori S. Muffly und Michaela Liedtke. „Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e19005-e19005. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e19005.
Der volle Inhalt der QuelleBaer, Maria R., Carleton C. Stewart, David Lawrence, Diane C. Arthur, John C. Byrd, Frederick R. Davey, Charles A. Schiffer und Clara D. Bloomfield. „Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)“. Blood 90, Nr. 4 (15.08.1997): 1643–48. http://dx.doi.org/10.1182/blood.v90.4.1643.
Der volle Inhalt der QuelleBaer, Maria R., Carleton C. Stewart, David Lawrence, Diane C. Arthur, John C. Byrd, Frederick R. Davey, Charles A. Schiffer und Clara D. Bloomfield. „Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)“. Blood 90, Nr. 4 (15.08.1997): 1643–48. http://dx.doi.org/10.1182/blood.v90.4.1643.1643_1643_1648.
Der volle Inhalt der QuelleWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Bercedis Peterson, John G. Gribben, Vicki A. Morrison, Kanti R. Rai, Richard A. Larson und John C. Byrd. „Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.“ Blood 114, Nr. 22 (20.11.2009): 539. http://dx.doi.org/10.1182/blood.v114.22.539.539.
Der volle Inhalt der QuelleCzuczman, Myron S., Pierluigi Porcu, Jeff Johnson, Donna Niedzwiecki, George P. Canellos und Bruce D. Cheson. „CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL.“ Blood 104, Nr. 11 (16.11.2004): 2486. http://dx.doi.org/10.1182/blood.v104.11.2486.2486.
Der volle Inhalt der QuelleFobare, Sydney, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Ramiro Garzon et al. „Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia“. Blood Advances 6, Nr. 5 (25.02.2022): 1371–80. http://dx.doi.org/10.1182/bloodadvances.2021006242.
Der volle Inhalt der QuellePeñaloza De La Torre, Ulises, und Gabriela Condori Condori. „Efecto antibacteriano del paramonoclorofenol alcanforado vs la asociación de hidróxido de calcioparamonoclorofenol alcanforado, sobre el cultivo in vitro de enterococcus faecalis“. Revista Médica Basadrina 10, Nr. 1 (08.05.2019): 16–19. http://dx.doi.org/10.33326/26176068.2016.1.590.
Der volle Inhalt der QuelleHylton, N., J. Blume, C. Gatsonis, R. Gomez, W. Bernreuter, E. Pisano, M. Rosen, H. Marques, L. Esserman und M. Schnall. „MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007“. Journal of Clinical Oncology 27, Nr. 15_suppl (20.05.2009): 529. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.529.
Der volle Inhalt der QuelleVenook, Alan P., Donna Niedzwiecki, Margarita Lopatin, Xing Ye, Mark Lee, Paula N. Friedman, Wendy Frankel et al. „Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581“. Journal of Clinical Oncology 31, Nr. 14 (10.05.2013): 1775–81. http://dx.doi.org/10.1200/jco.2012.45.1096.
Der volle Inhalt der QuelleNurhablisyah, Nurhablisyah, und Khikmah Susanti. „Analisis Pesan Visual pada Media Kampanye Luar Ruang Caleg 2019“. Magenta | Official Journal STMK Trisakti 3, Nr. 02 (26.07.2019): 478–86. http://dx.doi.org/10.61344/magenta.v3i02.49.
Der volle Inhalt der QuelleRodrigues, William Costa, und Paulo Cesar Rodrigues Cassino. „Parasitóides Associados a Cochonilhas e Aleirodídeos (Sternorrhyncha) de Plantas Cítricas no Estado do Rio de Janeiro“. EntomoBrasilis 5, Nr. 1 (21.03.2012): 33–36. http://dx.doi.org/10.12741/ebrasilis.v5i1.177.
Der volle Inhalt der QuelleSilverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, Richard M. Stone, Bayard L. Powell, Christy Mayo, Jay T. Backstrom und Richard A. Larson. „Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).“ Blood 106, Nr. 11 (16.11.2005): 1848. http://dx.doi.org/10.1182/blood.v106.11.1848.1848.
Der volle Inhalt der QuelleStock, Wendy, Jeffrey Johnson, Daohai Yu, Diane Bennett, Dorie Sher, Richard M. Stone, Jonathan E. Kolitz et al. „Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.“ Blood 106, Nr. 11 (16.11.2005): 1833. http://dx.doi.org/10.1182/blood.v106.11.1833.1833.
Der volle Inhalt der QuelleMarcucci, Guido, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum et al. „Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801“. Blood Advances 4, Nr. 4 (24.02.2020): 696–705. http://dx.doi.org/10.1182/bloodadvances.2019000492.
Der volle Inhalt der QuelleBattaglin, Francesca, Yasmine Baca, Joshua Millstein, Yan Yang, Joanne Xiu, Hiroyuki Arai, Jingyuan Wang et al. „CCR5andCCL5gene expression in colorectal cancer: comprehensive profiling and clinical value“. Journal for ImmunoTherapy of Cancer 12, Nr. 1 (Januar 2024): e007939. http://dx.doi.org/10.1136/jitc-2023-007939.
Der volle Inhalt der QuelleBlum, William, Ben Sanford, Rebecca B. Klisovic, Daniel J. DeAngelo, Geoffrey Uy, Bayard L. Powell, Wendy Stock et al. „Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)“. Blood 120, Nr. 21 (16.11.2012): 44. http://dx.doi.org/10.1182/blood.v120.21.44.44.
Der volle Inhalt der QuelleMarcucci, Guido, K. Mrózek, A. S. Ruppert, K. Maharry, J. E. Kolitz, R. J. Mayer, M. J. Pettenati et al. „t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study.“ Blood 104, Nr. 11 (16.11.2004): 2017. http://dx.doi.org/10.1182/blood.v104.11.2017.2017.
Der volle Inhalt der QuelleLozanski, Gerard, Ben Sanford, Daohai Yu, Rebecca Pearson, Colin Edwards, John C. Byrd, Richard A. Larson, Clara D. Bloomfield und Wendy Stock. „CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.“ Blood 108, Nr. 11 (01.11.2006): 2293. http://dx.doi.org/10.1182/blood.v108.11.2293.2293.
Der volle Inhalt der QuelleWilson, E., J. Crown, J. Ballot, D. McDonnell, E. Sheehan und J. Healy. „Estimating the real cost of adjuvant (A) trastuxumab (T) in patients(pts) with HER-2+ (H+) early stage breast cancer (ESBC)“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 6081. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6081.
Der volle Inhalt der QuelleDemichelis, Roberta, Karla Adriana Espinosa, Juan Rangel-Patiño, Emmanuel Almanza und Ana Cooke. „Pediatric-Inspired Regimens Are Associated with Better Outcomes When Compared with Hypercvad in Hispanic Adolescents and Young Adults with Acute Lymphoblastic Leukemia“. Blood 134, Supplement_1 (13.11.2019): 3877. http://dx.doi.org/10.1182/blood-2019-125370.
Der volle Inhalt der QuelleHarpole, D. H., R. Petersen, S. Mukherjee, A. Bild, H. Dressman, R. Kratzke, M. J. Kelley et al. „A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC)“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 7026. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7026.
Der volle Inhalt der QuelleBashey, Asad, Kouros Owzar, Jeffrey L. Johnson, Steven M. Devine, Richard K. Shadduck, Thomas C. Shea und Charles Linker. „Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.“ Blood 108, Nr. 11 (16.11.2006): 3122. http://dx.doi.org/10.1182/blood.v108.11.3122.3122.
Der volle Inhalt der QuelleMuffly, Lori, Jun Yin, Sawyer Jacobson, Anjali Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow et al. „Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data“. Blood 138, Supplement 1 (05.11.2021): 337. http://dx.doi.org/10.1182/blood-2021-148804.
Der volle Inhalt der QuelleRyan, Charles J., Sandipan Dutta, William Kevin Kelly, Rob Middleberg, Carly Russell, Eric Jay Small, Michael J. Morris, Mary-Ellen Taplin und Susan Halabi. „Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): 5067. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5067.
Der volle Inhalt der QuelleMalnassy, Greg, Susan Geyer, Noreen Fulton, Greg Koval, Donna Niedzwiecki, Victoria Carlton, Li Weng et al. „Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)“. Blood 122, Nr. 21 (15.11.2013): 2547. http://dx.doi.org/10.1182/blood.v122.21.2547.2547.
Der volle Inhalt der QuellePaschka, P., M. D. Radmacher, G. Marcucci, A. S. Ruppert, T. Vukosavljevic, S. P. Whitman, K. Mrózek, C. Liu, R. A. Larson und C. D. Bloomfield. „Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study“. Journal of Clinical Oncology 25, Nr. 18_suppl (20.06.2007): 7011. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7011.
Der volle Inhalt der QuelleSilverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, Erin P. Demakos, Neil T. Malone, James F. Holland und Richard A. Larson. „Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.“ Blood 106, Nr. 11 (16.11.2005): 2524. http://dx.doi.org/10.1182/blood.v106.11.2524.2524.
Der volle Inhalt der QuelleKhan, Abdul Moiz, Kyle Kondrat, Aditi Sharma und Jay Yang. „A Single Center, 10-Year Experience of CALGB-10403 Regimen in AYA Population with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia“. Blood 142, Supplement 1 (28.11.2023): 5822. http://dx.doi.org/10.1182/blood-2023-186830.
Der volle Inhalt der Quelle